These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3385720)

  • 21. Effects of tetrahydroaminoacridine (tacrine) derivatives and physostigmine in convulsions induced by pentylenetetrazol.
    Herink J; Koupilová M; Hrdina V
    Act Nerv Super (Praha); 1989 Dec; 31(4):303-5. PubMed ID: 2638124
    [No Abstract]   [Full Text] [Related]  

  • 22. Update on cholinergic enhancement therapy for Alzheimer disease.
    Read SL
    Bull Clin Neurosci; 1987; 52():34-7. PubMed ID: 3334548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Side effects of long acting cholinesterase inhibitors.
    Beermann B
    Acta Neurol Scand Suppl; 1993; 149():53-4. PubMed ID: 8128840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tacrine, a drug with therapeutic potential for dementia: post-mortem biochemical evidence.
    Francis PT; Bowen DM
    Can J Neurol Sci; 1989 Nov; 16(4 Suppl):504-10. PubMed ID: 2572313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Drug therapy of Alzheimer's disease. General concepts on nootropic drugs].
    Otomo E
    Nihon Rinsho; 1988 Jul; 46(7):1569-74. PubMed ID: 3221464
    [No Abstract]   [Full Text] [Related]  

  • 26. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease.
    Kumar V; Becker RE
    Int J Clin Pharmacol Ther Toxicol; 1989 Oct; 27(10):478-85. PubMed ID: 2684868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study.
    Fitten LJ; Perryman KM; Gross PL; Fine H; Cummins J; Marshall C
    Am J Psychiatry; 1990 Feb; 147(2):239-42. PubMed ID: 2405720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of tacrine-bifendate conjugates with improved cholinesterase inhibitory and pro-cognitive efficacy and reduced hepatotoxicity.
    Cen J; Guo H; Hong C; Lv J; Yang Y; Wang T; Fang D; Luo W; Wang C
    Eur J Med Chem; 2018 Jan; 144():128-136. PubMed ID: 29268129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First experience with the application of 7-methoxytacrine to psychiatric patients.
    Zapletálek M; Hanus H; Fusek J; Hrdina V
    Act Nerv Super (Praha); 1989 Dec; 31(4):305-6. PubMed ID: 2576923
    [No Abstract]   [Full Text] [Related]  

  • 31. Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results.
    Boller F; Forette F
    Biomed Pharmacother; 1989; 43(7):487-91. PubMed ID: 2684292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease.
    De Sousa M; Pirmohamed M; Kitteringham NR; Woolf T; Park BK
    Pharmacogenetics; 1998 Aug; 8(4):353-5. PubMed ID: 9731722
    [No Abstract]   [Full Text] [Related]  

  • 33. Fee-for-service research on THA: an explanation.
    Summers WK
    N Engl J Med; 1987 Jun; 316(25):1605-6. PubMed ID: 3587296
    [No Abstract]   [Full Text] [Related]  

  • 34. Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrines {11-amino-12-aryl-8,9,10,12-tetrahydro-7H-chromeno[2,3-b]quinolin-3-ols} for the potential prevention and treatment of Alzheimer's disease.
    Oset-Gasque MJ; González MP; Pérez-Peña J; García-Font N; Romero A; del Pino J; Ramos E; Hadjipavlou-Litina D; Soriano E; Chioua M; Samadi A; Raghuvanshi DS; Singh KN; Marco-Contelles J
    Eur J Med Chem; 2014 Mar; 74():491-501. PubMed ID: 24502897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's disease and caregiver time.
    Moore MJ; Clipp EC
    Lancet; 1994 Jan; 343(8891):239-40. PubMed ID: 7904698
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutic approaches to Alzheimer's disease. An informal survey of promising drug discovery strategies.
    Schehr RS
    Biotechnology (N Y); 1994 Feb; 12(2):140-4. PubMed ID: 7765319
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease.
    Romero A; Cacabelos R; Oset-Gasque MJ; Samadi A; Marco-Contelles J
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1916-22. PubMed ID: 23481643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer's disease.
    Wu WY; Dai YC; Li NG; Dong ZX; Gu T; Shi ZH; Xue X; Tang YP; Duan JA
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):572-587. PubMed ID: 28133981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tacrine in Alzheimer's disease].
    López de Munain A
    Rev Neurol; 1997 Jul; 25 Suppl 1():S70-2. PubMed ID: 9280671
    [No Abstract]   [Full Text] [Related]  

  • 40. Tacrine: In vivo veritas.
    Jarrott B
    Pharmacol Res; 2017 Feb; 116():29-31. PubMed ID: 28040533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.